{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-096921","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2025-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.415612+00:00","generated_at":"2026-05-17T04:40:58.936980+00:00","sec_items":["2.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Regeneron expects Q3 2025 pre-tax IPR&D charge of ~$83M, reducing EPS by $0.68","bullets":["Pre-tax acquired IPR&D charge of ~$83M for Q3 2025, primarily from $80M upfront to Hansoh Pharma.","Charge expected to reduce GAAP and non-GAAP diluted EPS by approximately $0.68 per share.","Preliminary results subject to financial statement closing procedures and may change.","Regeneron does not forecast such IPR&D charges due to uncertainty in timing and magnitude."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-096921","json":"https://secwatch.observer/filing/0001104659-25-096921.json","markdown":"https://secwatch.observer/filing/0001104659-25-096921.md","text":"https://secwatch.observer/filing/0001104659-25-096921.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000110465925096921/0001104659-25-096921-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000110465925096921/tm2528010d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:40:58.936980+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}